Nanobiotix reçoit un versement de 14 millions d’euros au titre de la deuxième tranche du prêt accordé par la Banque Européenne d’Investissement
04 mars 2019 13h17 HE
|
NANOBIOTIX
Nanobiotix reçoit un versement de 14 millions d’euros au titre de la deuxième tranche du prêt accordé par la Banque Européenne d’Investissement Renforcement du bilan et de la...
Arch Therapeutics to Provide Corporate Update at the 2019 BIO CEO & Investor Conference
05 févr. 2019 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Nanobiotix envisage de procéder à une offre au public aux Etats-Unis
16 janv. 2019 13h05 HE
|
NANOBIOTIX
Nanobiotix envisage de procéder à une offre au public aux Etats-Unis Paris, France, et Cambridge, Massachusetts (USA) le 16 janvier 2019 – NANOBIOTIX SA (Euronext: NANO – ISIN: FR0011341205),...
Nanobiotix Plans to Conduct Registered Public Offering in the United States
16 janv. 2019 13h05 HE
|
NANOBIOTIX
Nanobiotix Plans to Conduct Registered Public Offering in the United States Paris, France and Cambridge, Massachusetts (USA), January 16, 2019 – NANOBIOTIX SA (Euronext : NANO – ISIN :...
Nanobiotix et le MD Anderson Cancer Center annoncent une collaboration clinique globale de grande envergure portant sur NBTXR3
07 janv. 2019 14h09 HE
|
NANOBIOTIX
La collaboration comporte dans un premier temps neuf nouveaux essais cliniques de phase I/II avec NBTXR3, premier produit d’une nouvelle classe de Nanobiotix, dans six types de cancer différents -...
Nanobiotix and MD Anderson Cancer Center announce a large-scale, comprehensive clinical collaboration on NBTXR3
07 janv. 2019 14h09 HE
|
NANOBIOTIX
Collaboration will initially support nine new phase I/II clinical trials with Nanobiotix’s first-in-class agent NBTXR3 for use in treating six cancer types - head and neck, pancreatic, thoracic, lung,...
Arch Therapeutics to Provide Corporate Update at the 11th Annual Biotech Showcase™ 2019 Conference on January 8th, 2019
20 déc. 2018 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Arch Therapeutics Receives 510(k) Clearance from the US FDA for AC5™ Topical Gel
17 déc. 2018 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Arch Therapeutics Provided Corporate Update at the 11th Annual LD Micro Main Event
06 déc. 2018 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Arch Therapeutics Announces Positive Outcome of Ruling from Japanese Intellectual Property High Court
04 déc. 2018 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is...